Research on the Quality Risk Management of CDMO Enterprises CAR-T Cell Therapy Products in Co-Production

Wang Mei, Wu Zhi’ang

Chinese Pharmaceutical Affairs ›› 2025, Vol. 39 ›› Issue (7) : 756-763.

PDF(1044 KB)
PDF(1044 KB)
Chinese Pharmaceutical Affairs ›› 2025, Vol. 39 ›› Issue (7) : 756-763. DOI: 10.16153/j.1002-7777.2025-03-0006
Quality Management

Research on the Quality Risk Management of CDMO Enterprises CAR-T Cell Therapy Products in Co-Production

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2025, 39(7): 756-763 https://doi.org/10.16153/j.1002-7777.2025-03-0006

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(1044 KB)

Accesses

Citation

Detail
Sections
Recommended
京ICP备17052540号-4
Copyright © Chinese Pharmaceutical Affairs, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉